Open AccessChanging paradigm of immunooncology in advanced kidney cancer: nivolumab and ipilimumab combination in the first line therapy
Author(s) -
В. Б. Матвеев,
Maria Volkova,
А. С. Ольшанская
Publication year - 2019
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2019-15-1-125-130
Subject(s) - medicine , nivolumab , ipilimumab , temsirolimus , renal cell carcinoma , sunitinib , oncology , bevacizumab , immunotherapy , combination therapy , kidney cancer , alpha interferon , cancer , interferon , immunology , chemotherapy , discovery and development of mtor inhibitors , pi3k/akt/mtor pathway , apoptosis , biochemistry , chemistry